Press release
Injectable Drug Delivery Market Comprehensive Analysis 2018 Developments, Product Launches: Baxter International Inc., BD, Gerresheimer, Pfizer, SCHOTT, Alkermes, Eli Lilly and Company, Sandoz, Terumo Medical Corporation, Teva Pharmaceuticals, Ypsomed AG,
Injectable Drug Delivery Market
Global injectable drug delivery market is expected to reach USD 1,104,096.5 million by 2025 from USD 378,998.2 million in 2017, at a CAGR of 12.4% in the forecast period 2018 to 2025
By the help of SWOT analysis this report provides with a comprehensive insight about the Injectable Drug Delivery Market’s restrains and drivers all the keeping the report systematic and providing with the company profiles.
Click Here For Sample Copy of Report @: http://databridgemarketresearch.com/request-a-sample/?dbmr=global-injectable-drug-delivery-market
Market players for global injectable drug delivery market are listed below:
• Baxter International, Inc.,
• Becton Dickinson and Company,
• Gerresheimer AG,
• Pfizer, Inc.,
• Schott AG,
• Alkermes Plc.,
• Eli Lilly and Company,
• Sandoz,
• Terumo Corporation,
• Teva Pharmaceuticals Industries Ltd.
• Ypsomed,
• Bespak
BECTON, DICKINSON AND COMPANY
Founded in 1897 as Becton, Dickinson and Company and head quartered in New Jersey, U.S. is focused on developing, manufacturing and sales of medical supplies, devices, laboratory equipment and diagnostic products. The company operates through two business segments: BD Medical and BD Life Sciences. Its medical segment business unit includes Diabetes Care, Medication and Procedural Solutions, Medication Management Solutions, and Pharmaceutical Systems. These business units’ segmentsincludeneedles and syringes, intravenous catheters, self-injection system, insulin syringes and pen needles, prefilled IV flush syringes products.
PFIZER:
Incorporated in June 1942 and headquartered in New York, U.S. Pfizer Inc., is engaged in discovering, developing and, manufacturing of healthcare products. Pfizer Inc., operates through two segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The Company’s IH segment concentrates on creating and commercializing immunizations and prescriptions that enhance patients’ lives, and in addition products for the end user health care.
Its therapeutic regions incorporate oncology, antibodies, cardiovascular, metabolic, irritation, immunology, neuroscience, torment, uncommon illnesses and purchaser human services. The Company’s EH portion incorporates legacy brands that have lost or will soon lose market superiority in both rising and developed markets, biosimilars marked generics, generic sterile injectable products and mixture frameworks. EH segment additionally incorporates another EH innovative work association, and additionally contract manufacturing business.
BAXTER INTERNATIONAL:
Founded in 1931 and headquartered in Illinois, U.S., Baxter International, Inc. manufactures medical devices, pharmaceuticals, and biotechnology products. The company operates through two business segments, namely, BioScience and Medical Products. The company provides a wide range of products for the treatment of hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions.
Through the Medical Products segment, the company offers intravenous solutions, administration and nutrition sets, drug reconstitution systems, prefilled syringes (with and without needles) and vials, and infusion pumps and inhalation anesthetics. On the other hand, the BioScience business segment focuses on the treatment of hemophilia and other bleeding disorders by processing recombinant and plasma-based proteins.
Have Any Query? Ask Our Expert: http://databridgemarketresearch.com/inquire-before-buying/?dbmr=global-injectable-drug-delivery-market
Market is further segmented into:
• Type
• Usage Pattern
• End-User
• Mode of Administration
• Distribution Channel
• Application
• Geography
TABLE OF CONTENTS GLOBAL INJECTABLE DRUG DELIVERY MARKET
1. INTRODUCTION
2. MARKET SEGMENTATION
3. MARKET OVERVIEW
3.1. DRIVERS
3.2. RESTRAINTS
3.3. OPPORTUNITY
3.4. CHALLENGES
4. EXECUTIVE SUMMARY
5. PREMIUM INSIGHTS
6. GLOBAL INJECTABLE DRUG DELIVERY MARKET, REGULATORY
6.1. OVERVIEW
6.2. U.S. FDA APPROVAL
6.3. CE MARKING (EUROPEAN CONFORMITY)
6.4. EM (EUROPEAN MEDICINE AGENCY)
7. GLOBAL INJECTABLE DRUG DELIVERY MARKET, BY TYPE
7.1. OVERVIEW
7.2. INJECTABLE DRUG DELIVERY DEVICES
7.2.1. CONVENTIONAL INJECTION DEVICES
7.2.2. SELF INJECTION DEVICES
7.2.2.1. NEEDLE FREE INJECTORS (NFI)
7.2.2.2. AUTO INJECTORS
7.2.2.3. PEN INJECTORS
7.2.2.4. WEARABLE INJECTORS
7.3. INJECTABLE DRUG DELIVERY FORMULATION
7.3.1. CONVENTIONAL DRUG DELIVERY FORMULATIONS
7.3.1.1. SOLUTIONS
7.3.1.2. RECONSTITUTED/LYOPHILIZED FORMULATIONS
7.3.1.3. SUSPENSIONS
7.3.1.4. EMULSIONS
7.3.2. NOVEL DRUG DELIVERY FORMULATIONS
7.3.2.1. COLLOIDAL DISPERSIONS
7.3.2.2. MICROPARTICLES
7.3.2.3. LONG ACTING INJECTION FORMULATION
8. GLOBAL INJECTABLE DRUG DELIVERY MARKET, BY APPLICATION
8.1. OVERVIEW
8.2. GLOBAL INJECTABLE DRUG DELIVERY MARKET, BY APPLICATION
8.3. HORMONAL DISORDERS
8.3.1. INJECTABLE DRUGS FOR DIABETES
8.3.2. INJECTABLE DRUGS FOR ANEMIA
8.3.3. INJECTABLE DRUGS FOR REPRODUCTIVE HEALTH DISEASE
8.3.4. INJECTABLE DRUGS FOR ANTITHROMBOTIC/THROMBOLYTIC THERAPY
8.3.5. INJECTABLE DRUGS FOR OSTEOPOROSIS
8.3.6. INJECTABLE DRUGS FOR GROWTH HORMONE DISORDERS (GHD)
8.4. ONCOLOGY
8.5. AUTOIMMUNE DISEASES
8.5.1. INJECTABLE DRUGS FOR RHEUMATOID ARTHRITIS
8.5.2. INJECTABLE DRUGS FOR MULTIPLE SCLEROSIS
8.5.3. INJECTABLE DRUGS FOR CROHN’S DISEASES
8.5.4. INJECTABLE DRUGS FOR PSORIASIS
8.5.5. INJECTABLE DRUGS FOR OTHER AUTOIMMUNE DISEASES
8.6. ORPHAN DISEASE
8.7. OTHER APPLICATIONS
8.7.1. INJECTABLE DRUGS FOR PAIN MANAGEMENT
8.7.2. INJECTABLE DRUGS FOR ALLERGY TREATMENT
8.7.3. INJECTABLE DRUGS FOR AESTHETIC TREATMENTS
8.7.4. INJECTABLE DRUGS FOR HEPATITIS C
8.7.5. INJECTABLE DRUGS FOR HEMOPHILIA
9. GLOBAL INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN
9.1. OVERVIEW
9.2. CURATIVE CARE
9.3. IMMUNIZATIONS
9.4. OTHER USAGE PATTERN
10. GLOBAL INJECTABLE DRUG DELIVERY MARKET, BY MODE OF ADMINISTRATION
10.1. OVERVIEW
10.2. SKIN
10.3. CIRCULATORY/ MUSKOSKELETAL
10.4. ORGANS
10.5. CENTRAL NERVOUS SYSTEM
11. GLOBAL INJECTABLE DRUG DELIVERY MARKET, BY END USER
11.1. OVERVIEW
11.2. HOSPITALS AND CLINICS
11.3. HOME HEALTHCARE SETTINGS
11.4. RESEARCH LABORATORIES
11.5. PHARMACEUTICAL AND BIOTECHNOLOGICAL COMPANIES
11.6. OTHER END USERS
12. GLOBAL INJECTABLE DRUG DELIVERY MARKET, BY DISTRIBUTION CHANNEL
12.1. OVERVIEW
12.1.1. HOSPITAL PHARMACY
12.1.2. PHARMACY STORES
12.1.3. DIRECT TENDER
12.1.4. ONLINE PHARMACY
13. GLOBAL INJECTABLE DRUG DELIVERY MARKET, BY GEOGRAPHY
13.1. OVERVIEW
13.2. NORTH AMERICA INJECTABLE DRUG DELIVERY MARKET
13.3. EUROPE INJECTABLE DRUG DELIVERY MARKET
13.4. APAC INJECTABLE DRUG DELIVERY MARKET
13.5. SOUTH AMERICA INJECTABLE DRUG DELIVERY MARKET
13.6. MEA INJECTABLE DRUG DELIVERY MARKET
14. GLOBAL INJECTABLE DRUG DELIVERY MARKET, COMPANY SHARE
15. COMPANY PROFILES
15.1. BECTON, DICKINSON AND COMPANY
15.2. PFIZER
15.3. BAXTER INTERNATIONAL
15.4. GERRESHEIMER AG
15.5. SCHOTT AG INC.
15.6. ALKERMES INC.
15.7. ANTARES PHARMA
15.15. SANDOZ INTERNATIONAL GMBH
15.16. SANOFI
16. RELATED REPORTS
To Understand Complete Table Of Content, Tables And Figures @ https://databridgemarketresearch.com/toc/?dbmr=global-injectable-drug-delivery-market
Other Market Insights:
North America injectable drug delivery market is expected to reach USD 354.5 billion by 2024 from USD 154.0 billion in 2016, at a CAGR of 11.0% in the forecast period 2017 to 2024.
Read More: http://databridgemarketresearch.com/reports/north-america-injectable-drug-delivery-market/
About Data Bridge Market Research:
Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.
Contact:
Sopan Gedam
Data Bridge Market Research
Tel: +1-888-387-2818
Email: sopan.gedam@databridgemarketresearch.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Injectable Drug Delivery Market Comprehensive Analysis 2018 Developments, Product Launches: Baxter International Inc., BD, Gerresheimer, Pfizer, SCHOTT, Alkermes, Eli Lilly and Company, Sandoz, Terumo Medical Corporation, Teva Pharmaceuticals, Ypsomed AG, here
News-ID: 1389156 • Views: …
More Releases from Data Bridge Market Research
Precision gearbox market grow at a CAGR of 9.1% in the forecast period of 2022 t …
Precision gearbox market is expected to gain market growth in the forecast period of 2022 to 2029. Data Bridge Market Research analyses the market to reach at an estimated value of USD 5.9 billion by 2029 and grow at a CAGR of 9.1% in the above-mentioned forecast period.
Market Overview
This precision gearbox market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market…
Neuropathic Pain Market is expected to undergo a CAGR of 9.2% during the forecas …
Data Bridge Market Research analyses that the global neuropathic pain market, which was USD 5.86 billion in 2023, is expected to reach USD 11.86 billion by 2031, and is expected to undergo a CAGR of 9.2% during the forecast period of 2024 to 2031.
Market Overview
Neuropathic pain is a type of chronic pain caused by damage or dysfunction of the nervous system. It often presents as burning, shooting, or electric shock-kind…
Radiology market registering a CAGR of 6.20% during the forecast period of 2022- …
Radiology market was valued at USD 26.6 billion in 2021 and is expected to reach USD 43.04 billion by 2029, registering a CAGR of 6.20% during the forecast period of 2022-2029. The market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Market Overview
Radiology (also referred as diagnostic imaging) includes multiple tests are included in the process, which…
Cervical Retractors Market Size, Share, Trends, Key Drivers, Growth and Opportun …
Global Cervical Retractors Market report focuses on several essential parameters related to the market that includes but are not limited to a competitive landscape, brief segmentation and industrial infrastructure. This marketing report offers an in-depth overview of product specification, technology, product type and production analysis considering major factors such as revenue, cost, and gross margin. Cervical Retractors market is supposed to grow during the forecast period due to growing demand…
More Releases for DRUG
Alcohol Testing And Drug Testing Equipment Market 2025 Segmentation, Application …
Market Study Report, LLC, has compiled an exhaustive research study of the ‘Alcohol Testing And Drug Testing Equipment market’, detailing every single market driver and intricately analyzing the business vertical. This ‘Alcohol Testing And Drug Testing Equipment market’ study will aid in seeking out new business opportunities and fine-tuning existing marketing strategies through insights regarding SWOT analysis, market valuation, competitive spectrum, regional share, and revenue predictions.
Alcohol abuse and drug…
How much Diabetes Drug Market Impact Worldwide Medical Drug Industry?
Diabetes Drug Market From an insight perspective, the market report focuses on various levels of analyses — industry analysis, market rank analysis, and company profiles, which together comprise and discuss basic views on the competitive landscape, high-growth regions, and countries as well as their respective regulatory policies, Types ,Applications and opportunities in the market.
Diabetes is a metabolic disorder in which the body glucose level is elevated. There are two types of diabetes…
Hepatitis Drug Market Hepatitis Drug Clinical Pipeline Report 2023
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990
Report Table of Contents
1. Introduction to Hepatitis Disease
1.1 Prologue
1.1.1 History of Hepatitis
1.1.2 Causes of Hepatitis Disease
1.2 Types of Viruses which are Responsible for Hepatitis Disease
2. Global Prevalence of Hepatitis Infection
3. Available Drug Classes for Hepatitis Disease Treatment
3.1 Interferon Alfa Therapy
3.2 Protease Inhibitors Therapy
3.3 Polymerase…
Microcapsules Drug Delivery Market Microcapsules Drug Delivery Sales Report 2022
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990
Report Table of Contents
1. Indispensable Advent of Microcapsules
1.1 Trajectory of Microencapsulation
1.2 Why and wherefores for Microencapsulation
2. Characterization of Microcapsules
2.1 Composition of Microcapsules
2.2 Parameters Influencing Microcapsules
3. Engineering Technology of Microcapsules
3.1 Physical Manufacturing Technologies
3.2 Physicochemical and Chemical Technologies
4. Applicability of Microcapsules
4.1 Microcapsules in Pharmaceuticals
4.2 Microcapsules in Nutraceuticals
…
AstraZeneca’s NMOSD Drug receives orphan drug designation
April 18, 2017 Orphan Drug
European Medicine Agency has Announced orphan drug designation for inebilizumab (earlier known as MEDI-551) developed by AstraZeneca PLC (AZN) for the treatment of neuromyelitis optica spectrum disorder (NMOSD). The drug has already received orphan drug status from US Food and Drug Administration (FDA). NMOSD, also called Devic’s disease, is a rare, autoimmune disorder of the central nervous system (CNS) that affects the functioning…
Drug Discovery Strategies, PBPK Modeling and Drug-Drug Interaction Explored and …
This year’s 12th annual ADMET conference and exhibition promises to deliver appearances from experienced pharmaceutical professionals from ADME and PK/PD organisations such as AbbVie, GSK, Roche and Bayer when it returns to London this June.
The carefully selected speaker line up will be addressing early ADME application strategies and discussing the latest technologically advanced screening and testing models along with exploring ADMET technologies which will identify properties of a drug…
